Hysteroscopic Tubal Occlusion Using Amacrylate With or Without Lipidol in Patients With Hydrosalpinx Prior to IVF

Hysteroscopic Tubal Occlusion Using Iso-amyl- 2-cyanoacrylate With or Without Ethiodized Oil (Lipidol) in Patients With Hydrosalpinx Prior to IVF

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06130072

Enrollment

Registered

2023-11-13

Start date

2023-11-10

Completion date

2024-03-10

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effectiveness of Isoamyl-2-cyanoacrylate With and Without Ethiodized Oil in Occluding Hydrosalpinx Prior to IVF

Brief summary

Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate with or without Ethiodized oil (Lipidol) in patients with hydrosalpinx prior to IVF

Detailed description

hysteroscopic injection of iso-amyl- 2-cyanoacrylate with or without Ethiodized oil (Lipidol) in patients with hydrosalpinx requiring IVF. after one months and two months of the primary injection hysterosalpingography will be done to test for tubal occlusion.

Interventions

DRUGiso-amyl- 2-cyanoacrylate.

Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate in patients with hydrosalpinx prior to IVF

DRUGiso-amyl- 2-cyanoacrylate mixed with Ethiodized oil

iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Intervention model description

Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate with or without Ethiodized oil (Lipidol) in patients with hydrosalpinx prior to IVF

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 43 Years

Healthy volunteers

Yes

Inclusion criteria

• Infertile women due to tubal factor with hydrosalpinx (unilateral or bilateral) prepared for IVF

Exclusion criteria

* • Any patient with acute pelvic inflammatory disease, endometritis, lower genital tract infection. * The presence of intrauterine synechiae that might hinder the proper hysteroscopic examination and tubal cannulation diagnosed by diagnostic hysteroscopy. * The presence of uterine anomalies that might hinder the proper hysteroscopic examination and tubal cannulation diagnosed by diagnostic hysteroscopy. * Undiagnosed genital bleeding.

Design outcomes

Primary

Measure	Time frame	Description
Fallopian tube occlusion	one to three months	hysteosaplingographic diagnosis of tubal occlusion

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026